GRFS Grifols, S.A.
Grifols, S.A. (GRFS) is expected to report earnings on October 5, 2026, after the market close. The consensus earnings estimate is $0.27 per share.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Grifols, S.A.
Grifols SA is a specialty biopharmaceutical company that develops, manufactures and distributes a broad range of plasma derivative products. It operates in four business divisions: Bioscience, Diagnostic, Hospital and Raw Materials and Others.
Sector
Healthcare
Industry
Drug Manufacturers/Other
Charts powered in part by Lightweight Charts™ by TradingView.